In this webinar, take a deep dive into the downstream manufacturing processes for producing functional adeno-associated virus (AAV) capsids. Attendees will explore the different parameters that set apart ultracentrifugation from chromatography, including drug potency, vector yields, plasmid and host-cell deoxyribonucleic acid (DNA) levels and more. The featured speakers will also analyze scaling differences — how the two-column processes can be more readily scaled to 500-L and 1000-L bioreactors than the UC process.
TORONTO, June 13, 2024 /PRNewswire-PRWeb/ -- Improved analytical methods are helping improve the understanding of capsid heterogeneity in adeno-associated virus (AAV) therapeutic preparations. This understanding allows the development of manufacturing processes that produce AAV therapeutics with fewer non-functional capsids.
In this webinar, the speakers will present the results of a five-arm AAV9 comparability protocol that includes four alternative two-column downstream processes at 50-L scale and an ultracentrifugation (UC) process at 200-L scale. The UC process is the gold standard for functional capsid purification.
The expert speakers will outline simplified processes for both the capture and the empty/full (E/F) separation steps, including various combinations of cation exchange chromatography (CEX) and anion exchange chromatography (AEX) monoliths with different gradient types, as well as a process using an affinity resin and AEX monolith.
Also, the speakers will cover the analytical comparability of the drug substance lots, assessment of vector yields, host–cell proteins, plasmid and host-cell deoxyribonucleic acid (DNA) levels; capsid content by sedimentation-velocity analytical UC, charge detection mass spectrometry and mass photometry; vector protein purity by capillary electrophoresis; aggregation by size-exclusion chromatography; vector DNA purity by next-generation sequencing; potency by in vitro enhanced green fluorescent protein (eGFP) expression tests; and capsid protein charge heterogeneity and intact-capsid isoelectric point (pI) by capillary isoelectric focusing.
Register for this webinar today to gain insights into the production of AAV therapeutics using enhanced analytical methods with their role in reducing capsid heterogeneity.
Join Aleš Štrancar, Executive Managing Director, Sartorius BIA Separations, Joe Balleydier, Senior Vice President of Research and Development, Advanced Medicine Partners; and Mike Hatfield, Senior Director of Research and Development, Advanced Medicine Partners, for the live webinar on Thursday, June 27, 2024, at 10am EDT (3pm BST/UK)
For more information, or to register for this event, visit Comparability of Five Alternative AAV9 Downstream Processes, from Ultracentrifugation to Chromatography.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com/
SOURCE Xtalks
Share this article